ICHOM Standard Set for

LOCALIZED PROSTATE CANCER

Treatment approaches covered
Watchful waiting | Active surveillance | Prostatectomy | External beam radiation therapy | Brachytherapy | Androgen Deprivation Treatment | Focal therapy | Other

For a complete overview of the ICHOM Standard Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/Localized-Prostate-Cancer

Details
1. Recorded via the Clavien-Dindo-Classification
2. Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
3. Recommended to track via the Expanded Prostate Cancer Index Composite (EPIC 26 version preferred)
ICHOM Standard Set

CONTRIBUTORS

For more information about the process of developing a Standard Set, visit ichom.org/how-we-work/

The Sponsor

The Working Group

Australia
Ken Moretti | South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC); The Queen Elizabeth Hospital
Mark Frydenberg | Prostate Cancer Registry of Victoria; Monash University
Ian Ross | Melbourne Graduate School of Education, University of Melbourne; Cancer Action Victoria

Germany
Hartberg Huland & Markus Graefen | Martini-Klinik at University Medical Center Hamburg-Eppendorf
Michael Froehner | University Hospital Carl Gustav Carus, Technical University of Dresden
Günter Feick* | Bundesverband Prostatakrebs Selbsthilfe (BPS); Europa UOMO
Thomas Wagel | University Hospital Ulm

Ireland
Frank Sullivan | Galway University Hospital; Prostate Cancer Institute at NUI Galway
John Fitzpatrick | Irish Cancer Society

Israel
Jacob Ramon | Sheba Medical Center

Italy
Alberto Briganti | Vita-Salute San Raffaele University Hospital

Netherlands
Chris Bangma | Erasmus Medical Center

Sweden
Anna Bill-Axelson | Uppsala University Hospital; National Prostate Cancer Register (NPCR) of Sweden

United Kingdom
Adam Glaser | Leeds Teaching Hospitals NHS Trust
James Catto | Academic Urology Unit and Academic Unit of Molecular Oncology, CR-UK/YCR Sheffield Cancer Research Centre

United States
Steven Jay Frank | MD Anderson Cancer Center
David Swanson | MD Anderson Cancer Center
Andrew Vickers | Memorial Sloan-Kettering Cancer Center
Howard Sandler | Cedars-Sinai Medical Center
Michael Blute | Massachusetts General Hospital
Nancy Mendenhall | University of Florida Proton Therapy Institute

Ronald Chen | University of North Carolina Lineberger Comprehensive Cancer Center
Daniel Hamstra | University of Michigan Health System
Ashutosh Tewari | Icahn School of Medicine at Mount Sinai Hospital

Australia
Ken Moretti | South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC); The Queen Elizabeth Hospital
Mark Frydenberg | Prostate Cancer Registry of Victoria; Monash University
Ian Ross | Melbourne Graduate School of Education, University of Melbourne; Cancer Action Victoria

Germany
Hartberg Huland & Markus Graefen | Martini-Klinik at University Medical Center Hamburg-Eppendorf
Michael Froehner | University Hospital Carl Gustav Carus, Technical University of Dresden
Günter Feick* | Bundesverband Prostatakrebs Selbsthilfe (BPS); Europa UOMO
Thomas Wagel | University Hospital Ulm

Ireland
Frank Sullivan | Galway University Hospital; Prostate Cancer Institute at NUI Galway
John Fitzpatrick | Irish Cancer Society

Israel
Jacob Ramon | Sheba Medical Center

Italy
Alberto Briganti | Vita-Salute San Raffaele University Hospital

Netherlands
Chris Bangma | Erasmus Medical Center

Sweden
Anna Bill-Axelson | Uppsala University Hospital; National Prostate Cancer Register (NPCR) of Sweden

United Kingdom
Adam Glaser | Leeds Teaching Hospitals NHS Trust
James Catto | Academic Urology Unit and Academic Unit of Molecular Oncology, CR-UK/YCR Sheffield Cancer Research Centre

United States
Steven Jay Frank | MD Anderson Cancer Center
David Swanson | MD Anderson Cancer Center
Andrew Vickers | Memorial Sloan-Kettering Cancer Center
Howard Sandler | Cedars-Sinai Medical Center
Michael Blute | Massachusetts General Hospital
Nancy Mendenhall | University of Florida Proton Therapy Institute

Ronald Chen | University of North Carolina Lineberger Comprehensive Cancer Center
Daniel Hamstra | University of Michigan Health System
Ashutosh Tewari | Icahn School of Medicine at Mount Sinai Hospital

*Patient representative